In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/t....

Our best ideas are those that we believe offer the highest risk-adjusted returns over a 12-month timeframe supported by a higher-than-average level of confidence. They are our most preferred sector exposures. Refer to our recently published Winter 2....

EBR has completed interim enrolment in its pivotal SOLVE trial and has also shored-up its financing, with access to up to US$50m in venture debt. Completing interim trial enrolment on time represents a key milestone, with interim trial results (1QCY....

Top Credit Stories BANKS - Termination of coverage CONSUMER - Termination of coverage FINANCIALS - Termination of coverage HIGH YIELD - Termination of coverage: INDUSTRIALS - Termination of coverage  

Xero is a challenger small to medium-sized business (SMB) accounting platform. Its vision is to " be the most insightful and trusted small business platform”. All going to plan, there is plenty of upside on subscriber adds (increased penetratio....

Following a review of our research universe, we discontinue coverage of Paradigm Biopharmaceuticals. Our forecasts, target price and recommendation should no longer be relied upon for investment decisions.